J Gen Intern Med
Published 2012:27(7):863-60.
DOI: 10.1007/s11606-011-1966-4
(c) Society of General Internal Medicine 2012
Erratum to: J Gen Intern Med
DOI: 10.1007/s11606-011-1966-4
On page 857 of the original publication, the following statement contains a technical error.
Recently, the FDA approved Nuedexta, a fixed-dose combination of the cough suppressant dextromethorphan hydrobromide and the antiarrhythmic quinidine sulfate, for treatment of pseudobulbar affect in patients with amyotrophic lateral sclerosis or multiple sclerosis.
Correction: Although the FDA approved Nuedexta based on studies in amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), the approved indication was for treatment of pseudobulbar affect (without restriction to a specific underlying condition).
Footnotes
The online version of the original article can be found at 10.1007/s11606-011-1966-4.